USFDA nod to Granules India Metoprolol Succinate ER Tablets

Published On 2023-08-09 06:00 GMT   |   Update On 2023-10-06 11:38 GMT
Advertisement

Telangana: Granules India has announced that the US Food & Drug Administration (US FDA) has approved the Company’s Abbreviated New Drug Application (ANDA) for Metoprolol Succinate ER Tablets 25/50/100/200 mg.

It is therapeutically equivalent to the reference listed drug, Toprol-XL Extended-Release Tablets, 25 mg, 50 mg, 100 mg and 200 mg, of Sequel Therapeutics, LLC.
The Company had filed two ANDAs for the same product with different technologies. This is the second ANDA approval for
Advertisement
Metoprolol Succinate
ER tablets that is therapeutically equivalent to the RLD, Toprol- XL, ER tablets for Granules.

Read also: Granules India arm bags USFDA nod for Acetaminophen and Ibuprofen Tablets

Granules India Limited, incorporated in 1991 is a vertically integrated Indian pharmaceutical company headquartered at Hyderabad. The company is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). Its products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, U.S. and U.K. The Company has 8 manufacturing facilities out of which 6 are located in India and 2 are in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL.

Read also: USFDA nod to Granules India Seizure drug Levetiracetam

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News